Blood Coagulation Analyzer Market Outlook:
Blood Coagulation Analyzer Market size was valued at USD 5.4 billion in 2025 and is projected to reach USD 8.8 billion by the end of 2035, rising at a CAGR of 5.5% during the forecast period, i.e., 2026-2035. In 2026, the industry size of blood coagulation analyzer is estimated at USD 5.7 billion.
The worldwide occurrence of cardiovascular diseases, blood disorders, and the rising demand for effective hemostasis management in both clinical and surgical settings are the key factors propelling growth in the blood coagulation analyzer market. The NIH article published in April 2023 stated that Hemophilia A is the most common congenital coagulopathy, which affects around 1 in 5,000 males, whereas Hemophilia B, also known as Christmas disease, impacts about 1 in 30,000 male births, thereby positively influencing market expansion.
Furthermore, the market is also benefiting from the expanding use of point-of-care testing and the growing focus on personalized medicine, which requires precise coagulation monitoring. In this regard, the report from NBDF revealed that the annual costs of treatment for bleeding disorders averaged USD 300,000 for those with severe hemophilia. The report further stated that for individuals who develop inhibitors, costs can exceed USD 1 million per year.
Blood Coagulation Analyzer Market - Growth Drivers and Challenges
Growth Drivers
- Escalating aging demographics: The increasing occurrence of hemophilia, thrombocytopenia, von Willebrand disease, and other coagulation-related disorders among the aging demographics is the primary driver for the market. As evidence, the report from the World Health Organization in February 2025 estimates that people aged 60 and older are expected to increase from 1.1 billion in 2023 to 1.4 billion by the end of 2030, especially in developing economies, hence denoting a wider market scope.
- Cutting-edge technological breakthroughs: The amplifying discoveries with the utilization of AI, automation, and point-of-care testing are transforming the growth dynamics in the blood coagulation analyzer market. For instance, in April 2024, HemoSonics reported that it had received Special 510(k) clearance from the U.S. FDA for the expanded use of arterial blood samples with its Quantra QStat Cartridge that enables hospitals to further standardize and operationalize viscoelastic testing with an arterial and venous indication.
- Increasing awareness & investments: The ever-increasing investments in healthcare infrastructure and growing awareness about coagulation disorders are readily boosting the progression of the blood coagulation analyzer market. In May 2024 NHLBI reported that its Blood Diseases & Disorders Education Program aims to raise national awareness of conditions such as anemia and sickle cell disease, supporting both patients and healthcare professionals. Besides, through the Blood Health Network, it engages diverse partners to expand community-level outreach and education, hence denoting a positive market outlook.
Historic Age at Diagnosis of Hemophilia in Children Under 2 Years (U.S., 2012-2018)
|
Age Group |
% Diagnosed |
|
Less than 1 month |
69.7% |
|
1-6 months |
15.6% |
|
7-12 months |
7.1% |
|
12-24 months |
4.7% |
|
Prenatal |
2.8% |
Source: CDC
Public Health Funding Requests for Blood Disorders Research and Programs
|
Program |
Funding Request |
Purpose/Impact |
|
National Institutes of Health (NIH) |
USD 49.048 billion for FY 2023 |
Supports biomedical research crucial for advancing treatments for blood disorders |
|
Centers for Disease Control and Prevention (CDC) - Sickle Cell Data Collection Program |
USD 10 million for FY 2025 |
Improves understanding of health outcomes and healthcare utilization for sickle cell disease |
Source: AMH
Challenges
- High cost of the testing equipment: This is one of the primary challenges associated with the blood coagulation analyzer market, especially in developing nations. The cost of maintenance, operations in the completely automated and high-throughput systems is extremely high, making it challenging for small-scale manufacturers to adopt them. In addition, these devices necessitate regular calibration, quality control, and expensive reagents, which further cause substantial operational expenses.
- Shortage of skilled workforce: Despite the presence of continued advancements in automation, the interpretation of coagulation tests still requires a trained workforce, which is lacking in the blood coagulation analyzer market. Besides the shortage of skilled laboratory technicians, especially in developing regions, this hinders optimal use of analyzers, which may result in diagnostic errors or delayed reporting. The absence of proper standardization in these devices can also lead to inconsistent results, thereby causing hindrance to the market upliftment in almost all nations.
Blood Coagulation Analyzer Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
5.5% |
|
Base Year Market Size (2025) |
USD 5.4 billion |
|
Forecast Year Market Size (2035) |
USD 8.8 billion |
|
Regional Scope |
|
Blood Coagulation Analyzer Market Segmentation:
End user Segment Analysis
Based on end user hospitals & diagnostic centers segment is predicted to garner the largest revenue share of 55.5% in the blood coagulation analyzer market during the discussed time frame. The dominance of the segment is attributable to the high patient pool necessitating surgeries, emergency care, and chronic disease management, which requires coagulation monitoring. Besides, these facilities are the primary point of care for anticoagulation therapy management that requires frequent testing, hence denoting a wider segment scope.
Product Type Segment Analysis
In terms of product type automated analyzer segment is projected to gain a significant share of 48.6% in the market by the end of 2035. The high demand for accuracy, efficiency, and high-throughput testing is the key factor behind the leadership. In June 2024, HORIBA reported that it had expanded its Yumizen H550 hematology analyzer range with new models called H550E, H500E CT, and H500E O, which feature an integrated Erythrocyte Sedimentation Rate (ESR) testing alongside CBC/DIFF analysis, thus denoting a positive market outlook.
Test Type Segment Analysis
The prothrombin time test is expected to grow at a considerable rate, with a share of 32.4% in the blood coagulation analyzer market during the discussed timeframe. The subtype is the gold standard for monitoring warfarin therapy, which is one of the most commonly prescribed oral anticoagulants. The January 2024 NIH article revealed that the test is extremely crucial for assessing coagulation status, particularly in patients receiving vitamin K antagonists such as warfarin, thereby assisting in the diagnosis and management of various hematologic and bleeding disorders.
Our in-depth analysis of the blood coagulation analyzer market includes the following segments:
|
Segment |
Subsegments |
|
End user |
|
|
Product Type |
|
|
Test Type |
|
|
Technology |
|
|
Application |
|
|
Portability |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Blood Coagulation Analyzer Market - Regional Analysis
North America Market Insights
North America is predicted to capture the largest revenue share of 35.9% in the global blood coagulation analyzer market by the end of 2035. The dominance of the region is attributable to the increasing investments in this sector and the well-established healthcare infrastructure. In this regard, the American Society of Hematology (ASH) in June 2025 revealed that it has committed over USD 12 million to address critical research funding gaps and support the next generation of hematologists. Besides, this investment includes a USD 9 million increase in awards funding, expanding support to over 600 researchers at all career stages.
The U.S. is readily blistering growth in the regional blood coagulation analyzer market on account of a huge focus on advancing diagnostic capabilities through digital transformation and automation. For instance, in April 2025, Daxor Corporation reported that it had submitted the next-generation blood volume analyzer called Daxor BVA to the U.S. FDA, thereby advancing its mission to optimize healthcare through precise fluid management, hence benefiting the overall market growth.
Canada is also continuously growing in the blood coagulation analyzer market due to the widespread adoption, especially for monitoring international normalized ratio (INR) levels. In June 2024, the country’s government announced that it invests USD 5 million annually in Canadian Blood Services to support research that addresses donation barriers and advances treatments for blood disorders such as leukemia and lymphoma. It also stated that this research aims to maintain a safe, effective blood supply and strengthen healthcare access, hence suitable for standard market growth.
Historic Epidemiological Statistics on Hemophilia in the U.S. (2012-2018)
|
Category |
Statistic |
|
Estimated Prevalence |
~33,000 males living with hemophilia in the U.S. |
|
Most Common Type |
Hemophilia A (3-4× more common than Hemophilia B) |
|
Severe Cases (All Types) |
Just over 40% of males with hemophilia have the severe form |
Source: CDC
APAC Market Insights
Asia Pacific is considered to be the fastest-growing region in the global blood coagulation analyzer market from 2026 to 2035. The region’s upliftment in this field is readily attributable to the expanding healthcare dynamics, escalating investments in diagnostics, and the rising occurrence of cardiovascular and bleeding disorders. Due to the presence of a vast patient population, the region is witnessing an increasing demand for early diagnosis and monitoring, with great support from government healthcare policies and increasing private sector participation.
China is the central player in the region’s blood coagulation analyzer market, which is driven by a rise in coagulation-related diseases and a rapidly aging population, and strategic collaborations. In December 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. announced that it had successfully acquired 75% controlling stake in DiaSys Diagnostic Systems GmbH, which is an in-vitro diagnostics company that enhances the company’s supply chain, broadens its in-vitro diagnostics product portfolio, and accelerates market growth.
India also holds a strong position in the Asia Pacific’s blood coagulation analyzer market owing to the increasing awareness of blood disorders, the expansion of diagnostic facilities, and the rising prevalence of lifestyle diseases affecting coagulation. In April 2025, the Ministry of Social Justice & Empowerment stated that it organized nationwide awareness programs through its National Institutes and Composite Regional Centres, which are aimed at improving diagnosis, treatment, and care for bleeding disorders, with a special focus on women and girls, thereby strengthening the country’s position in this field.
Awareness Programmes on Bleeding Disorders Across India on World Haemophilia Day - 2025
|
Location/Institute |
Activities Conducted |
Participants/Focus |
|
SVNIRTAR, Cuttack |
Awareness program for healthcare professionals, students, and the public; expert discussions on haemophilia |
Healthcare professionals, students, general public |
|
NILD, Kolkata |
Awareness program, webinar, health talk on symptoms and prevention |
~130 patients (Divyangjan) and caregivers |
|
NIMHR, Sehore |
Educational, cultural, and community-based events |
General community |
|
CRC Nellore |
Awareness sessions for nursing students, a blood donation camp in collaboration with the Indian Red Cross Society |
~150 participants, including staff, trainees, and parents |
|
CRC Tripura |
Awareness program with institute officials and experts |
General public |
|
CRC Rajnandgaon |
Blood donation camp |
Local community |
|
NIEPID, Navi Mumbai |
Webinar on “Haemophilia: Care and Rehabilitation” |
Healthcare and related professionals |
|
CRC Davangere, CRC Jaipur, and others |
A series of awareness programs |
General public |
Source: MoSJE
Europe Market Insights
Europe is continuing its growth trajectory in the blood coagulation analyzer market, owing to the advancements in coagulation analyzer technologies and an aging population, and constant efforts from the domestic pioneers to scale up distribution. In April 2024, Siemens Healthineers and Sysmex Corporation have independently begun distributing their combined hemostasis testing systems in Europe, marking a key milestone in their 25+ year strategic partnership to provide high-, mid-, and low-volume laboratories with advanced hemostasis testing platforms such as the CN-3000/6000, CS-2500, CS-5100, and CA-600 series.
Germany grabbed the largest share in Europe’s blood coagulation analyzer market, facilitated by its strong healthcare infrastructure, high adoption rates of diagnostic technologies, and a focus on research and innovation. In July 2024, Perosphere Technologies Inc. signed a distribution agreement with CoRRect Medical GmbH to introduce its novel Point-of-Care Coagulometer in the country, which enables reagent-free, bedside coagulation diagnostics, supporting real-time treatment decisions, especially for patients on direct oral anticoagulants.
The U.K. is also a key contributor to progression in the regional blood coagulation analyzer market due to the higher rates of obesity, increased awareness of diagnostic methods, and a growing patient population suffering from blood diseases. In May 2025, the country’s Government published its final response to the Infected Blood Inquiry’s 2024 report, accepting all twelve of its recommendations. The report also stated that the government has paid £96.6 million in compensation, in addition to £1.2 billion in interim payments, and has allocated £11.8 billion, thereby marking one of the most comprehensive compensation schemes in modern history.
Key Blood Coagulation Analyzer Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The international market of blood coagulation analyzers is extremely consolidated, wherein the top five players captured the largest revenue shares. The key strategies implemented by these pioneers include intense R&D for high-throughput systems with integrated workflow solutions. Besides, the leading firms such as Roche, Siemens, and Abbott are deliberately focusing on the expansion of their product portfolios through strategic acquisitions and partnerships, thereby expanding their geographical reach.
Below is the list of some prominent players operating in the global market:
|
Company Name |
Country |
Market Share (2024) |
Industry Focus |
|
Roche Diagnostics |
Switzerland |
11.7% |
Provides integrated Coba’s system solutions for coagulation testing in central labs |
|
Siemens Healthineers |
Germany |
10.6% |
Offers a broad portfolio of diagnostic instruments, including ADVIA coagulation systems |
|
Abbott Laboratories |
U.S. |
9.4% |
Develops diagnostic solutions, including point-of-care and lab-based coagulation analyzers |
|
Danaher Corporation (Beckman Coulter) |
U.S. |
8.5% |
Manufactures automated coagulation analyzers like the ACL TOP Series for clinical labs |
|
Thermo Fisher Scientific |
U.S. |
6.4% |
Provides diagnostic instruments and reagents for clinical and research laboratories |
|
Instrumentation Laboratory (Werfen) |
U.S./Spain |
xx% |
Specializes in hemostasis diagnostics with ACL and HemosIL product lines |
|
Bio-Rad Laboratories |
U.S. |
xx% |
Supplies quality controls, reagents, and systems for coagulation testing |
|
Mindray |
China |
xx% |
Global provider of medical devices, including automated coagulation analysis systems |
|
F. Hoffmann-La Roche AG |
Switzerland |
xx% |
Provides integrated Cobas system solutions for coagulation testing in central labs |
|
Becton, Dickinson and Company (BD) |
U.S. |
xx% |
Focuses on point-of-care testing platforms that can include coagulation parameters |
|
Grifols |
Spain |
xx% |
Provides transfusion medicine and clinical diagnostics equipment, including coag analyzers. |
|
ERBA Diagnostics |
Germany |
xx% |
Manufactures Mannheim and ErbaLachema brand coagulation analyzers and reagents |
|
Accriva Diagnostics (Werfen) |
U.S. |
xx% |
(Part of Werfen) Focused on point-of-care coagulation testing solutions |
|
Samsung Medison |
South Korea |
xx% |
A subsidiary offering in-vitro diagnostic equipment, including coagulation systems |
|
Transasia Bio-Medicals |
India |
xx% |
Leading Indian IVD company manufacturing a range of coagulation analyzers |
|
Biosensors International |
Malaysia/Singapore |
xx% |
Develops medical devices, with R&D in monitoring technologies |
Below are the areas covered for each company in the market:
Recent Developments
- In March 2025, Sysmex America, Inc., notified that it has expanded its 3-part differential automated hematology analyzer line with the XQ-320 for reliable and accurate CBC testing, which is the first 3-part differential analyzer with BeyondCare Quality Monitor.
- In December 2024, Erba Transasia Group announced the launch of its Erba H7100, an advanced hematology analyzer that is designed to improve clinical diagnostics through higher throughput of 70-90 tests per hour, the inclusion of reticulocyte parameters for diagnosing anemias, and an Optical Platelet (Plt-O) to correct pseudo-thrombocytopenia.
- Report ID: 8085
- Published Date: Sep 11, 2025
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
Blood Coagulation Analyzer Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
